Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Down 16.2% in February

Lyell Immunopharma, Inc. (NASDAQ:LYEL) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 8,090,000 shares, a decrease of 16.2% from the February 13th total of 9,650,000 shares. Currently, 6.5% of the shares of the company are short sold. Based on an average trading volume of 1,160,000 shares, the days-to-cover ratio is currently 7.0 days.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating and set a $1.00 price target on shares of Lyell Immunopharma in a research note on Thursday, March 13th.

Lyell Immunopharma Stock Performance

Shares of Lyell Immunopharma stock traded down $0.03 on Tuesday, hitting $0.49. 550,649 shares of the company’s stock were exchanged, compared to its average volume of 1,040,421. The stock has a market capitalization of $143.78 million, a PE ratio of -0.62 and a beta of -0.41. Lyell Immunopharma has a 1 year low of $0.48 and a 1 year high of $3.15. The company has a 50-day simple moving average of $0.62 and a 200-day simple moving average of $0.90.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The company had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. On average, analysts expect that Lyell Immunopharma will post -0.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in LYEL. Centiva Capital LP bought a new stake in Lyell Immunopharma during the 3rd quarter worth approximately $31,000. Graham Capital Management L.P. bought a new stake in shares of Lyell Immunopharma during the 4th quarter valued at $33,000. RPO LLC purchased a new position in shares of Lyell Immunopharma during the 4th quarter valued at $42,000. Intech Investment Management LLC bought a new position in Lyell Immunopharma in the 3rd quarter worth $52,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Lyell Immunopharma in the 3rd quarter worth $52,000. 66.05% of the stock is currently owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.